Cardiac disease diagnosis

cTnI/CK-MB/MYO Test Kit

Time-Resolved Fluorescent Immunochromagraphic Assay

【General Information】

1.Method: Time-resolved Fluorescent Immunochromatographic Method 

2.Bio-marker tested: cardiac troponin I (cTnI), creatine kinase (CK-MB), myoblobin (MYO) 

3.Clinical Sample: whole blood, serum or plasma 

4.Other Specifications: in vitro, quantitative test

【Clinical significance】

1. "Golden Standard" to diagnose myocardial infarction (MI) 

2. Assess infarct size and ACS risks 

3. Diagnose reinfarction or infarct extension 

4. Diagnosis of myocardial injury in perioperative period and perinatal period 

5. As myocardial infarction (AMI) early detection indicators, highly sensitive 

6. Diagnose reinfarction or infarct extension 

7. Determine myocardial reperfusion


1. Advanced: time-resolved fluorescence immunoassay quantitative chromatography 

2. Quantitative: quantitative detection of cardiac troponin I (cTnI), creatine kinase (CK-MB) and myoblobin (MYO) 

3. Accurate: well correlated with imported chemiluminescence reagent (r> 0.975)  

4. High sensitivity: lower detection limit <0.05 ng/mL (cTnI) , <0.25 ng/mL (CK-MB) and <1.0 ng/mL (MYO) 

5. Simple: simple operation, suitable for bedside detection 

6. Widely applicable : outpatient laboratory, emergency laboratory, medical center, cardiology, ICU, and etc 


Mar. 2014

CFDA approvals for five immunoassay reagents adaptable to most chemical analyzers were obtained

Feb. 2014

CFDA approvals for time-resolved fluorescence immunochromatographic analyzer were obtained

Sep. 2013

Lumigenex passed The first Food and Drug Administration by the Suzhou Municipal Quality Management System Assessment